Company achieved #7 ranking among fastest-growing companies in the Americas with strong revenue growth from 2021-2024, expanded treatment offerings, demonstrated market demand, and backing from prominent venture capital firms (Founders Fund and 8VC). Recognition validates business model and market opportunity.
Articles that tag MMS but are mainly about other companies.
Posted mixed Q3 fiscal 2026 results with adjusted EPS of $2.22 slightly beating consensus by 0.9% but total revenues of $1.28B missed consensus by 3.2% and declined 5.1% year-over-year, indicating revenue weakness despite modest earnings beat.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
